These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 16320123)

  • 1. Stroke, amyotrophic lateral sclerosis and epilepsy.
    Tear S; Shah S
    IDrugs; 2005 Dec; 8(12):966-7. PubMed ID: 16320123
    [No Abstract]   [Full Text] [Related]  

  • 2. Preliminary investigation of effect of granulocyte colony stimulating factor on amyotrophic lateral sclerosis.
    Zhang Y; Wang L; Fu Y; Song H; Zhao H; Deng M; Zhang J; Fan D
    Amyotroph Lateral Scler; 2009; 10(5-6):430-1. PubMed ID: 19922135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Too much, too soon?
    Govindarajan R; Galvez-Jimenez N
    Muscle Nerve; 2011 Jul; 44(1):149; author reply 149-50. PubMed ID: 21674531
    [No Abstract]   [Full Text] [Related]  

  • 4. Granulocyte colony-stimulating factor.
    Kaptan K; Beyan C; Ifran A
    CMAJ; 2006 Oct; 175(9):1095; author reply 1095-6. PubMed ID: 17060662
    [No Abstract]   [Full Text] [Related]  

  • 5. Granulocyte colony-stimulating factor.
    Harriss JP
    CMAJ; 2006 Oct; 175(9):1095; author reply 1095-6. PubMed ID: 17060661
    [No Abstract]   [Full Text] [Related]  

  • 6. Pilot study of granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood stem cells in amyotrophic lateral sclerosis (ALS).
    Cashman N; Tan LY; Krieger C; Mädler B; Mackay A; Mackenzie I; Benny B; Nantel S; Fabros M; Shinobu L; Yousefi M; Eisen A
    Muscle Nerve; 2008 May; 37(5):620-5. PubMed ID: 18335482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrathecal upregulation of granulocyte colony stimulating factor and its neuroprotective actions on motor neurons in amyotrophic lateral sclerosis.
    Tanaka M; Kikuchi H; Ishizu T; Minohara M; Osoegawa M; Motomura K; Tateishi T; Ohyagi Y; Kira J
    J Neuropathol Exp Neurol; 2006 Aug; 65(8):816-25. PubMed ID: 16896315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical development of levetiracetam for amyotrophic lateral sclerosis.
    Davies SL; Moral MA
    Drug News Perspect; 2006 Nov; 19(9):572-3. PubMed ID: 17220961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Changing neurology--from diagnostic to therapeutic discipline].
    Smits A; Andsberg G; Andersen PM; Andersson M; Fredrikson S; Gunnarsson M; Kumlien E; Lycke J; Jensen SM; Remahl IN; Nyholm D
    Lakartidningen; 2008 Sep 3-9; 105(36):2413-6. PubMed ID: 18831452
    [No Abstract]   [Full Text] [Related]  

  • 10. [On the therapeutic use of the nucleosides, cytidine and uridine, in some neurological diseases].
    Monticone GF; Bergamasco B; Cognazzo A
    Minerva Med; 1966 Dec; 57(101):4348-52. PubMed ID: 5958226
    [No Abstract]   [Full Text] [Related]  

  • 11. New targets for established proteins: exploring G-CSF for the treatment of stroke.
    Schäbitz WR; Schneider A
    Trends Pharmacol Sci; 2007 Apr; 28(4):157-61. PubMed ID: 17350693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are multiple sclerosis and amyotrophic lateral sclerosis autoimmune disorders of endogenous vasoactive neuropeptides?
    Staines DR
    Med Hypotheses; 2008; 70(2):413-8. PubMed ID: 17582695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrathecal delivery of hepatocyte growth factor from amyotrophic lateral sclerosis onset suppresses disease progression in rat amyotrophic lateral sclerosis model.
    Ishigaki A; Aoki M; Nagai M; Warita H; Kato S; Kato M; Nakamura T; Funakoshi H; Itoyama Y
    J Neuropathol Exp Neurol; 2007 Nov; 66(11):1037-44. PubMed ID: 17984685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-drug therapy in amyotrophic lateral sclerosis: combinations of multiple, untested drugs should not be used at this time.
    Shefner JM
    Muscle Nerve; 2004 Nov; 30(5):676-8. PubMed ID: 15452839
    [No Abstract]   [Full Text] [Related]  

  • 15. The (endo)cannabinoid system in multiple sclerosis and amyotrophic lateral sclerosis.
    Centonze D; Rossi S; Finazzi-Agrò A; Bernardi G; Maccarrone M
    Int Rev Neurobiol; 2007; 82():171-86. PubMed ID: 17678961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyotrophic lateral sclerosis: where are we now?
    Miller R
    Int J Clin Pract Suppl; 1998 Apr; 93():3-5. PubMed ID: 9691242
    [No Abstract]   [Full Text] [Related]  

  • 17. [Incidence of hereditary factors in 2 diseases of unknown etiology: amyotrophic lateral sclerosis & multiple sclerosis].
    BARBIZET J
    Concours Med; 1958 Dec; 80(50):5369-72. PubMed ID: 13609147
    [No Abstract]   [Full Text] [Related]  

  • 18. Naloxone of no benefit in amyotrophic lateral sclerosis.
    Silani V; Perini M; Fayoumi ZM; Scarlato G
    Ann Neurol; 1983 Feb; 13(2):222. PubMed ID: 6830194
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug development for amyotrophic lateral sclerosis: lessons from cancer therapy.
    Kaye S
    Int J Clin Pract Suppl; 1998 Apr; 93():6-8. PubMed ID: 9691243
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical and experimental neuroprotection in neurodegenerative diseases is a therapeutic option for the future of amyotrophic lateral sclerosis (ALS). Preface.
    Ludolph AC; Drory VE
    J Neurol; 2000 Dec; 247 Suppl 6():VI/1. PubMed ID: 19714407
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.